Testimony of the Department of Commerce and Consumer Affairs

Before the
Senate Committee on Judiciary
Tuesday, February 25, 2020
12:30 p.m.
State Capitol, Conference Room 016

On the following measure:
S.B. 2284, S.D. 1, RELATING TO HEALTH CARE INSURANCE

WRITTEN TESTIMONY ONLY

Chair Rhoads and Members of the Committee:

My name is Colin Hayashida, and I am the Insurance Commissioner of the Department of Commerce and Consumer Affairs' (Department) Insurance Division. The Department offers comments on this bill.

The purpose of this bill is to prohibit a health care insurer, mutual benefit society, or health maintenance organization from requiring an insured, a subscriber, a member, or an enrollee diagnosed with stage two through stage four cancer to undergo step therapy prior to covering the insured for the drug prescribed by the insured's health care provider, under certain conditions.

By prohibiting step therapy under certain conditions, this measure may create the potential for circumvention of medical necessity provisions in Hawaii Revised Statutes (HRS) section 432E-1.4. Section 432E-1.4(a) provides in relevant part, “A health intervention may be medically indicated and not qualify as a covered benefit or meet the
definition of medical necessity. A managed care plan may choose to cover health interventions that do not meet the definition of medical necessity.” This bill may be construed as prohibiting step therapy without considering whether it is medically necessary.

The Department is in the process of establishing contact with the federal Department of Health and Human Services (HHS) to seek guidance on state-required benefits. The HHS recently proposed rulemaking to the Patient Protection and Affordable Care Act (PPACA) that addresses states’ defrayment and obligations. The HHS proposed rule would require states to annually report to HHS “any state-required benefits applicable to the individual and/or small group market that are considered in addition to [the essential health benefits].”¹

For the Committee’s information, HRS section 23-51 provides in part that “[b]efore any legislative measure that mandates health insurance coverage for specific health services, specific diseases, or certain providers of health care services as part of individual or group health insurance policies, can be considered, there shall be concurrent resolutions passed requesting the auditor to prepare and submit to the legislature a report[.]”

Thank you for the opportunity to testify on this bill.

¹ See Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans (HHS Notice). This document was published on February 6, 2020 and has a comment period that ends on March 2, 2020. The PDF version is available at: https://www.federalregister.gov/documents/2020/02/06/2020-02021/benefit-and-payment-parameters-notice-requirement-for-non-federal-governmental-plans.
<table>
<thead>
<tr>
<th>Submitted By</th>
<th>Organization</th>
<th>Testifier Position</th>
<th>Present at Hearing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doris Segal Matsunaga</td>
<td>Testifying for Save Medicaid Hawaii</td>
<td>Support</td>
<td>No</td>
</tr>
</tbody>
</table>

Comments:
Dear Members of the Senate Judiciary Committee,

I strongly support the passage of SB 2284, SD1. This is an important bill to support the individual with cancer diagnosed with stage two through stage four cancer to get the best prescribed drug that is consistent with best practices for the treatment of the cancer or treatment of side effects of the cancer. It is patient focused and that is what health care delivery should be about.

Thank you for the opportunity to testify.
SENATE COMMITTEE ON CONSUMER PROTECTION AND HEALTH
Sen. Karl Rhodes, Chair
Sen. Jarrett Keohokalole, Vice Chair

Date: February 25, 2020
Time: 12:30 p.m.
Place: Conference Room 016

From: Hawaii Medical Association
    Elizabeth A Ignacio, MD, Chair, HMA Legislative Committee
    Christopher Flanders, DO, Executive Director

Re: SB2284 SD1 - Relating to Health Care Insurance
Position: SUPPORT

On behalf of Hawaii’s physician and student members, the HMA supports SB2284 SD1 which would prohibit health care insurers from requiring an insured diagnosed with Stage II – IV cancer from undergoing step therapy prior to covering the insured for the drug prescribed by the insured’s health care provider.

Step therapy, or “fail first” therapy is a form of prior authorization that requires preferred drugs be prescribed first until proven ineffective before physicians can try other, potentially higher cost agents. For cancer patients, selecting the proper personalized treatment as quickly as possible can be critical to survival. Delays in getting patients the right treatments at the right time many times leads to unnecessary complications in the physician-patient decision-making process.

Step therapy likewise places a significant administrative burden on physician practices. Physicians do not currently have ready access to patient benefit and formulary information, as there is currently not the capability of making this information available through electronic health records or other means at the point of prescribing. This lack of transparency makes it exceedingly difficult to determine what treatments are preferred by a particular payor at the point of care and places practices at financial risk for the cost of administered drugs if claims are later denied for unmet (yet unknown) step therapy requirements.

Furthermore, payor exemption and appeals processes can be complicated and lengthy, making them burdensome for both busy physician practices and patients awaiting treatment. It is our hope that another layer of administrative complication will not be added on an already strained system.

Thank you for allowing the Hawaii Medical Association to testify on this issue.
February 3, 2020

The Honorable Rosalyn H. Baker, Chair
The Honorable Stanley Chang, Vice Chair
Senate Committee on Commerce, Consumer Protection, and Health

Senate Bill 2284 – Relating to Health Care Insurance

Dear Chair Baker, Vice Chair Chang, and Members of the Committee:

The Hawaii Association of Health Plans (HAHP) appreciates the opportunity to testify on SB 2284, which prohibits a health care insurer, mutual benefit society, or health maintenance organization from requiring an insured, subscriber, member, or enrollee diagnosed with stage two through stage four cancer to undergo step therapy prior to covering the insured for the drug prescribed by the insured's health care provider, under certain conditions.

We would like to express concerns on this legislation as it goes against policies as determined by the health plan’s medical director and generally accepted evidence based medical practice.

As this is a new mandated benefit, it is subject to an impact assessment report by the Legislative Auditor pursuant to Sections 23-51 of the Hawaii Revised Statutes.

Thank you for allowing us to testify expressing concerns on SB 2284.

Sincerely,

HAHP Public Policy Committee
February 23, 2020

The Honorable Karl Rhoads, Chair
The Honorable Jarrett Keohokalole, Vice Chair
Senate Committee on Judiciary

Re: SB 2284, SD1 – Relating to Health Care Insurance

Dear Chair Rhoads, Vice Chair Keohokalole, and Committee Members:

Hawaii Medical Service Association (HMSA) appreciates the opportunity to testify on SB 2284, SD1, which prohibits a health care insurer, mutual benefit society, or health maintenance organization from requiring an insured, subscriber, member, or enrollee diagnosed with stage two through stage four cancer to undergo step therapy prior to covering the insured for the drug prescribed by the insured's health care provider, under certain conditions, for health insurance policies and contracts issued or renewed after 12/31/2020.

HMSA does not require step therapy for oncology treatment. HMSA works to ensure our members have the care and treatment they need that is safe and efficacious. We appreciate the sensitivity and skill necessary to treat cancer and defer treatment decisions to oncologists. We foster open discussion and dialogue with local oncologists whom we meet with annually for feedback on our internal policies and guidelines.

Our policies follow evidence-based clinical guidelines and are in line with national best practice guidelines issued by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). The ASCO is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer and the NCCN is a not-for-profit alliance of the 28 leading cancer centers including MD Anderson, Mayo Clinic Cancer Center, and Memorial Sloan Kettering Cancer Center. Our medical policies are not intended to dictate to providers how to practice medicine in this area.

HMSA believes that this measure impedes our ability to continue to establish medical policies based on evidence-based medicine and best practices. Should this bill move forward, we respectfully ask that the measure be amended to remove the mandate and request the State Auditor to first conduct an impact assessment report pursuant to Section 23-51 of the Hawaii Revised Statutes.

Thank you for the opportunity to provide testimony on this measure.

Sincerely,

Pono Chong
Vice President, Government Relations
To: Hawaii State Senate Committee on Judiciary, Consumer Protection, and Health
Hearing Date/Time: Tuesday, 02-25-20 12:30PM
Place: Hawaii State Capitol, Room 016
Re: Judith Ann Armstrong is in support of SB2284 SD1 RELATING TO HEALTH CARE INSURANCE.

Aloha Senator Karl Rhoads, Vice Chair Jarrett Keohokalole, and Members of the Committee,

I, Judith Armstrong, am writing in strong support of SB2284 SD1.

Medical treatment decisions should be made by Medical Professionals not Insurance Companies. Perhaps the passage of this bill will encourage the Insurance Companies to support tests that would identify patients with cancer in its earliest stage when there is the best chance of successful intervention to save the patient.

I strongly urge our legislators to support this important benefit change.

Thank you for this opportunity to testify in support of this important measure.

Sincerely,
Judith Ann Armstrong
1717 Ala Wai Blvd
Apt 3006
Honolulu, HI 96815